Long-term Follow-up Study of Patients Receiving CAR-T Cells

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03375619

Enrollment

500

Registered

2017-12-18

Start date

2017-12-01

Completion date

2035-01-01

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burkitt Lymphoma, Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Small Lymphocytic, Lymphomas Non-Hodgkin's B-Cell, Mantle Cell Lymphoma, Multiple Myeloma

Keywords

CAR-T Cell Therapy, chimeric antigen receptor

Brief summary

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)

Detailed description

The objective is to follow participants receiving CAR-T cells from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.

Interventions

OTHERLong-Term Follow-Up of Participants who Received CAR-T cells

No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* All participants who enrolled in a CAR-T study at Froedtert Hospital & the Medical College of Wisconsin.

Exclusion criteria

* There are no

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in the incidence of a new malignancy at 5 years.	Baseline to five years.	The number of subjects with new malignancy.
Change from baseline in the incidence of a new malignancy at 10 years.	Baseline to 10 years.	The number of subjects with new malignancy.
Change from baseline in the incidence of a new malignancy at 15 years.	Baseline to 15 years.	The number of subjects with new malignancy.

Countries

United States

Contacts

Primary ContactMedical College of Wisconsin Clinical Cancer Center

cccto@mcw.edu414-805-8900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026